In addition, Bortezomib is also able to block proteasome-dependent p100 conversion to p52 resulting in inhibition of non-canonical NFκB activity suggesting the importance of Bortezomib on NFκB signaling in MM. Here, NFKB1 is linked to Miyoshi myopathy.